Refine Search
Clear Filters
Content Type












Sites















Refine Search
Clear Filters
Content Type












Sites















200 of 288 Results
ASHP Recommends

Get Involved in a Meeting

Article

Submit a proposal for an educational session, poster, or management case study. Get involved and present at an ASHP meeting today.

HDAC Inhibitor Approved for Multiple Myeloma

News Article

FDA and Novartis on Monday announced the approval of panobinostat, a histone deacetylase (HDAC) inhibitor, for the third-line treatment of multiple myeloma.

Sagent Recalls Atracurium Vials

News Article

Sagent Pharmaceuticals Inc. on Monday announced it was recalling six lots of atracurium besylate 10-mg/mL injection vials because an FDA inspection of the contract

Guidelines on Election Communications Balance Visibility With Fairness

News Article

With the start of the 2015 election season at ASHP, the Board of Directors has released guidelines on campaign decorum along with a FAQ.

FDA Approves New Fibrin Sealant

News Article

FDA and The Medicines Company on April 30 announced the approval of Raplixa, a fibrin sealant product, to help control mild-to-moderate bleeding during surgical

New Recombinant Factor IX Product Approved to Help Hemophilia B Patients

News Article

FDA on April 29 approved the biologics license application for the recombinant coagulation factor IX product known as Ixinity, by Cangene Corporation.

Study Findings on Acetaminophen at Odds With Clinical Guidelines

News Article

A recently published report in The BMJ concludes that acetaminophen doesn't do much to relieve low back pain or pain from osteoarthritis of the hip or knee despite

Pharmacies Erred in Preparing Ceftolozane-Tazobactam Doses, FDA Says

News Article

FDA announced Wednesday that pharmacy personnel have misinterpreted the phrase "1 g/0.5 g per vial" on the vial and carton labeling of ceftolozane–tazobactam for

FDA Warns of Serious Acidosis Risk for Diabetes Medication Class

News Article

A May 15 Drug Safety Communication from FDA warns that sodium–glucose cotransporter-2 (SGLT2) inhibitors, a recently approved class of antidiabetic medications,